erus BioSciences(CHRS) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update – Net revenue of $77.1 million in Q1 2024 – – CRI and ENB Therapeutics development partnership for toripalimab in ovarian cancer – – New debt and royalty financing replaces$75 million term loan, with debt maturity of May 2029 – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., May 9, 2024 -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for ...